TY - JOUR
T1 - Therapy with 177Lu-DOTATATE
T2 - Clinical implementation and impact on care of patients with neuroendocrine tumors
AU - Kendi, A. Tuba
AU - Halfdanarson, Thorvardur R.
AU - Packard, Annie
AU - Dundar, Ayca
AU - Subramaniam, Rathan M.
N1 - Funding Information:
R. M. Subramaniam was a principal investigator for the 177Lu-DOTATATE expanded access program supported by Advanced Accelerator Applications, a Novartis company, and is a principal investigator for clinical trials sponsored by Endocyte Inc. and GE Healthcare.
Publisher Copyright:
© American Roentgen Ray Society
PY - 2019
Y1 - 2019
N2 - OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of patients with neuroendocrine tumors. CONCLUSION. Most well differentiated and some moderately and poorly differentiated neuroendocrine tumors express large numbers of somatostatin receptors on their cell surfaces. PRRT targets these cells with 177Lu-DOTATATE, which is a medium-energy beta emitter. Since this agent received U.S. Food and Drug Administration approval in 2018, tremendous effort has been exerted at institutions throughout the United States toward proper implementation of this promising therapy. This review summarizes clinical implementation of PRRT and its impact on patient care.
AB - OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of patients with neuroendocrine tumors. CONCLUSION. Most well differentiated and some moderately and poorly differentiated neuroendocrine tumors express large numbers of somatostatin receptors on their cell surfaces. PRRT targets these cells with 177Lu-DOTATATE, which is a medium-energy beta emitter. Since this agent received U.S. Food and Drug Administration approval in 2018, tremendous effort has been exerted at institutions throughout the United States toward proper implementation of this promising therapy. This review summarizes clinical implementation of PRRT and its impact on patient care.
KW - Lu-DOTATATE
KW - Lutetium 177
KW - Neuroendocrine tumors
KW - Peptide receptor radionuclide therapy
UR - http://www.scopus.com/inward/record.url?scp=85070180176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070180176&partnerID=8YFLogxK
U2 - 10.2214/AJR.19.21123
DO - 10.2214/AJR.19.21123
M3 - Review article
C2 - 31039017
AN - SCOPUS:85070180176
SN - 0361-803X
VL - 213
SP - 309
EP - 317
JO - The American journal of roentgenology and radium therapy
JF - The American journal of roentgenology and radium therapy
IS - 2
ER -